283 related articles for article (PubMed ID: 31290664)
1. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
Huang D; Gaul DA; Nan H; Kim J; Fernández FM
J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model.
Jones CM; Monge ME; Kim J; Matzuk MM; Fernández FM
J Proteome Res; 2015 Feb; 14(2):917-27. PubMed ID: 25567202
[TBL] [Abstract][Full Text] [Related]
3. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
Kim J; Coffey DM; Ma L; Matzuk MM
Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
[TBL] [Abstract][Full Text] [Related]
4. Machine Learning Reveals Lipidome Remodeling Dynamics in a Mouse Model of Ovarian Cancer.
Bifarin OO; Sah S; Gaul DA; Moore SG; Chen R; Palaniappan M; Kim J; Matzuk MM; Fernández FM
J Proteome Res; 2023 Jun; 22(6):2092-2108. PubMed ID: 37220064
[TBL] [Abstract][Full Text] [Related]
5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
6. Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors.
Lanfredi GP; Thomé CH; Ferreira GA; Silvestrini VC; Masson AP; Vargas AP; Grassi ML; Poersch A; Candido Dos Reis FJ; Faça VM
Biochim Biophys Acta Proteins Proteom; 2021 Jun; 1869(6):140623. PubMed ID: 33607274
[TBL] [Abstract][Full Text] [Related]
7. Improving the cytological diagnosis of high-grade serous carcinoma in ascites with a panel of complementary biomarkers in cell blocks.
Zhang X; Chen L; Liu Y; Xu Y; Zhang X; Shi Y; Wang C; Zhang PL; Liu Y
Cytopathology; 2018 Jun; 29(3):247-253. PubMed ID: 29280203
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
[TBL] [Abstract][Full Text] [Related]
9. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
10. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
[TBL] [Abstract][Full Text] [Related]
11. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
12. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
13. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
[TBL] [Abstract][Full Text] [Related]
14. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R
Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451
[TBL] [Abstract][Full Text] [Related]
15. Space- and Time-Resolved Metabolomics of a High-Grade Serous Ovarian Cancer Mouse Model.
Sah S; Ma X; Botros A; Gaul DA; Yun SR; Park EY; Kim O; Moore SG; Kim J; Fernández FM
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565391
[TBL] [Abstract][Full Text] [Related]
16. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
[TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
[TBL] [Abstract][Full Text] [Related]
18. Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
Kobayashi H; Ogawa K; Kawahara N; Iwai K; Niiro E; Morioka S; Yamada Y
Free Radic Res; 2017 Oct; 51(9-10):755-764. PubMed ID: 28931330
[TBL] [Abstract][Full Text] [Related]
19. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
[No Abstract] [Full Text] [Related]
20. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]